Gilead Sciences, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Gilead Sciences, Inc. (GILD) holds an ST Score of 49.2 out of 100 (C+), with its strongest factor being Sentiment (A+) and its weakest Profitability (D-). Analysts rate GILD Buy across 58 ratings with a $150.00 average price target (-0.0% vs the current $150.56).
- Strongest
- SentimentA+
- Weakest
- ProfitabilityD-
All factor grades
- SentimentA+
- MomentumB+
- GrowthB-
- ForecastC+
- ValuationC-
- Financial StrengthD+
- ProfitabilityD-
- Piotroski5/9
Contact
GILD stock: frequently asked questions
What is GILD's ST Score?
Gilead Sciences, Inc. (GILD) has an ST Score of 49.2 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GILD a buy, sell, or hold?
Wall Street's consensus rating on GILD is Buy based on 58 analyst ratings. Our own ST Score grades it C+ (49.2/100). This is data, not investment advice — always do your own research.
What is GILD's valuation grade?
Gilead Sciences, Inc. (GILD) earns a valuation grade of C-, measured against Drug Manufacturers - General peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GILD's growth grade?
Gilead Sciences, Inc. (GILD) earns a growth grade of B-, measured against Drug Manufacturers - General peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GILD's profitability grade?
Gilead Sciences, Inc. (GILD) earns a profitability grade of D-, measured against Drug Manufacturers - General peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GILD's financial strength grade?
Gilead Sciences, Inc. (GILD) earns a financial strength grade of D+, measured against Drug Manufacturers - General peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GILD?
The average analyst price target for Gilead Sciences, Inc. (GILD) is $150.00 from 58 analysts, which is -0.0% versus the recent price of $150.56.
What is GILD's Piotroski score?
Gilead Sciences, Inc. (GILD) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.